Agent inducing maturing of dendritic cells

FIELD: medicine.

SUBSTANCE: invention concerns medicine, be more specific to oncology, and concerns the substances stimulating maturing of dendritic cells (DC). Application of fucoidan from Fucus evanescens or polysaccharide composition from Fucus evanescens consisting of fucoidan in amount of 60-80% and poly-mannuronic acid in amount of 20-40%, as an agent possessing ability to induce maturing of dendritic cells is offered. The declared fucoidan preparations have a standardised composition and, hence, possess direct biological effect. They keep the properties for long time (3 years).

EFFECT: increase of DC functional activity under the influence of the declared substances.

8 dwg


The invention relates to medicine, specifically to Oncology, and applies to substances that stimulate the maturation of dendritic cells (DC).

Studies have shown that the use of dendritic cells in cancer therapy has promising results. Dendritic cells - cells of the immune protection is a potential antigen presenting cells (APC) and play a major role in the regulation of the immune response [Banchereau J., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000. 18. 767-811].

Dendritic cells there are at least two functionally and phenotypically different stages of development and maturation. At the first stage of immature dendritic cells (iD) circulate in the blood, and then penetrate into the peripheral tissues, where they learn the ability to capture and pressure antigens. In further Mature dendritic cells (mDC) migrate to the lymph nodes, presenterat peptide fragments of antigens with molecules of T lymphocytes inducyruya immune response. The ability of DC to stimulate T cells depends on their stage of maturation.

When dendritic cells are fully Mature, they are a source of information about the content of cancer cells. In many types of cancer dendritic cells in the cancerous area are immature and not able to effectively convey information about cancer cells balances the immune system, particularly T-lymphocytes. To t the th to information about cancer was reliable, DC cells to Mature - this is the main point. So getting a large number of Mature DC cells from the circulating blood of patients cancer patients appears to be an important moment in the immunotherapy of cancer.

Monocytes cultured with cytokines (interferons, tumor necrosis factor (TNF), a number of interleukins, colony-stimulating factor (CSF)) differentiate into immature dendritic cells. The DC maturation occurs after the processing of their substances, inducing maturation of dendritic cells, such as tumor necrosis factor (TNF-α), γ-interferon (IFN-γ), or CD40L (the family of tumor necrosis factor) [Reis e Sousa C: Dendritic cells in a mature age. Nat. Rev. Immunol. 2006. 6(6). 476-483].

Known use as an agent for the maturation of dendritic cells bacilli Calmette-guérin (BCG), compounds of imidazoquinolines, artificial donateware of polyribonucleotide, and lipopolysaccharide [EN 2005121256 A, 2006.02.10].

It is known that fucoidan from Fucus vesiculosus (Sigma) inhibits the binding T epithelial cells to CD11b/CD18, purified from neuropile, and also increases the viability of DC production of IL-12 TNF-alpha, MHC I and II, CD54 and CD86. Also this fucoidan reduces absorption of antigen and increases the growth of allogeneic splenocytes, shows immunostimulating effect and affect the maturation of DC on the way, including NF-kappa-B activation [Kim, M.H., and Joo, H.G. Immunostimulatory effects of fucoidan on bne marrow-derived dendritic cells. Immunol. Lett. (2008), 115, 138-143].

The objective of the invention is the expansion of the means of inducing the maturation of dendritic cells.

The problem is solved by the use of fucoidan from Fucus evanescens or polysaccharide composition of Fucus evanescens, consisting of fucoidan in the amount of 60-80% and polymannuronic acid in the amount of 20-40%, as a means of inducing the maturation of dendritic cells.

Technical result provided by the invention, is expressed in inducing the activity of fucoidan from Fucus evanescens or polysaccharide composition of Fucus evanescens on the maturation of dendritic cells.

Fucoidan from Fucus evanescens, denoted hereinafter "Fe", patented by the applicant as a means of having anticoagulant and immunotropic effect [EN 2247574 C2, 10.03.2005].

Polysaccharide composition of Fucus evanescens, consisting of fucoidan in the amount of 60-80% and polymannuronic acid in the amount of 20-40%, indicated hereinafter "Fc", patented by the applicant as a biologically active product, which is an additional source of immunoactive polysaccharides and soluble dietary fibers, which increase nonspecific resistance of the organism [EN 2315487 C1, 2008.01.27].

The claimed technical solution is new, as available in the patent and scientific and medical literature is not detected description application product Fe or Fc in image quality is as funds inducing the maturation of dendritic cells.

For the specialist is not obvious from the prior art, the possibility of using Fe or Fc as a means of inducing the maturation of dendritic cells.

The fucoidans is a family vysokotarifitsirovannyh Homo - and heteropolysaccharides brown algae, having L-fucose as the main structural units, but differ from each other physico-chemical properties, monosaccharide composition, molecular mass and other characteristics. This family can be added new connections, obtained from various species of brown algae, with their intrinsic physico-chemical and other characteristics, and with certain biologically active properties.

It is established that the manifestation of biological activity in any specific effects of certain types of algae does not imply that this biological activity will occur in fucoidans isolated from other species of algae. This is confirmed by, for example, research on the linkages between the structure of fucoidans from various sources and their biological activity [Cumashi, A., Ushakova, N. A. et. al. (2007) A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology 17, 541-552].

The authors of the above is the Uta article shows which of the nine investigated fucoidans only five show inhibition of thrombin activity. It was also shown that the fucoidans decrease of leukocytes with peritonitis in rats. The possible mechanism of this action is inhibition of P-selectin binding activity. The activity of fucoidans were decreased in the next row: L. saccharina, L. digitata, F. evanescens, F. serratus, F. distichus, F. spiralis, A. nodosum. The fucoidans from Cladosiphon okamuranus and Fucus vesiculosus showed no inhibition of P-selectin binding activity.

Thus, the proposed solution meets the criterion of "inventive step".

Fucoidan from Fucus vesiculosus (Sigma), denoted hereinafter "Fv"is a non-homogeneous product. It contains a mixture of fucoidans and uronic acids, as well as the impurity neugeborne nature [Fitton, J.H. Fucoidans: healthful saccharides from the sea. GlycoScience&Nutrition (2005), 6, 1-6]. This circumstance does not allow an unambiguous conclusion about what fucoidan, and not another component of this mixture, induces the maturation of dendritic cells.

Preparations Fe and Fc are standardized composition and, therefore, have directed the biological effect. They do not contain polysaccharides another nature, lipids and retain their properties for a long time (3 years). All these advantages open the possibility for application of fucoidan from Fucus evanescens or Polish IGNOU songs from Fucus evanescens as a means of inducing the maturation of dendritic cells.

The invention is illustrated by the following drawings:

Figure 1 shows the induction of maturation of dendritic cells under the influence of drugs Fe and Fc. Fv - drug comparison; lipopolysaccharide (LPS) - positive control.

Figure 2 presents the dose-dependent effect of Fc on the maturation of dendritic cells.

Figure 3 is a diagram of the induction of markers of dendritic cells under the action of Fc and LPS.

Figure 4 is a diagram of the induction of markers of dendritic cells using the methods of electron microscopy with the use of PI-conjugated CD 80 antibody and FITC-conjugated MHC-II antibodies.

Figure 5 presents the phagocytic activity of dendritic cells under the action of Fc and LPS.

Figure 6 presents the expression of cytokines in dendritic cells treated with Fc and LPS.

Figure 7 presents the expression of IFN-γ in the mixed lymphocyte culture under the action of Fc and LPS.

On Fig presents the growth stimulation of T cells under the action of dendritic cells treated with Fc and LPS.

The invention is illustrated in the example.


TNF-αThe tumor necrosis factor
CD40LThe family of tumor necrosis factor
iDCImmature dendritic cells
mDCMature dendritic cells
BCGBacillus Calmette-guérin
CD1Cluster of differentiation 1
CD3Cluster of differentiation 3
CD14Cluster of differentiation 14
CD40Cluster of differentiation
CD80Cluster of differentiation
CD86Cluster of differentiation
GM-CSFGranulocyte-macrophage colony-stimulating factor
MHC-IIThe major histocompatibility complex
CCR7Chemokinesis receptor 7
IL-10Interleukin 10
IL-12Interleukin 12
PBSPhosphate buffer

Obtaining dendritic cells

Monocytes were purified from peripheral blood cells selection using super-paramagnetic media MACS (Miltenyi Biotec., Bergisch Gladbach, Germany)conjugated with antibodies to CD 14 (cluster of differentiation 14). The purity of monocytes, certain flow cytometer, more than 95%. Monocytes were cultured in medium containing recombinant GM-CSF (800 u/ml) (Novartis, Munich, Germany) and IL-4 (125 u/ml) (Strathmann Biothec., Hamburg, Germany) for 6 days to generate DC. Differentiation of monocytes was tested by expression of CD1 and CD 14.

Analysis of the phenotype of dendritic cells

Cells (1×106) were collected, washed with phosphate buffer (PBS)containing bovine serum albumin (BSA)and labeled with FITC (fluoresceinisothiocyanate) and RE (phycoerythrin)-conjugated antibodies by incubation on ice for 30 min followed by washing in PBS. Viable cells would and analyzed on a FACSCalibur flow cytometer (Beckton Dickinson, Franklin lakes, NJ). Appropriate antibodies were used as a control for nonspecific staining. Drugs Fv and Fc increased the level of expression of cluster of differentiation of CD40, CD80, CD83 in dendritic cells like LPS. However, the Fe had a lesser effect on the expression of markers of dendritic cells than Fv and Fc. The expression of MHC II (major histocompatibility complex) did not increase under the effect of fucoidans (Figure 1). The expression of CD80, CD83 iDC increased depending on the doses Fc (Figure 2). In addition, Fc increased the expression of CD80, CD83, CD86 and CCR7 (chemokine receptor 7) in dendritic cells (Figure 3).

Confocal microscopy

Cells were fixed for 15 min in 3% solution of paraformaldehyde in PBS, incubated 10 min in 0.1% solution of Triton X-100 in PBS. Slides were incubated in blocking buffer at 25°C for one hour. After washing (3 times with PBS), the cells were incubated at 4°C for one hour with PE-conjugated antibodies against CD-89 or MHC-II and again washed with PBS. The samples were analyzed using microscopy (Carl Zeiss LSM 510). Treatment of dendritic cells with Fc drug for two days induces typical morphological changes during maturation of dendritic cells (Figure 4). Immunohistochemical analysis showed that the immunoreactivity CD86 and MHC-II significantly increased after two days of cultivation with fucoidan F and lipopolysaccharide.

Phagocytic activity

For analysis of endocytosis 1×105cells were incubated with 1 mg/ml FITC-dextran (42 kDa) at 37°C for one hour. Cells were washed twice with cold HBSS, incubated, and analyzed on a flow cytometer. A parallel experiment was conducted at 4°C.

FITC-dextran was tested for its ability to penetrate into cells. Phagocytic activity of DC treated with Fc, was higher than in control (Figure 5).

Analysis of cytokines

Cells were incubated in medium RPMI-1640 containing Fc (50 μg/ml) or LPS (1 μg/ml) for 24 h in the presence or in the absence of T cells. Profiles of cytokine secretion of IL-10, IL-12, TNF-a, IFN-g in solutions were measured in three independent experiments using ELISA kits (R&D System), the sensitivity of ≥ 5 PCG/ml Standard cytokines were used as controls. The expression level of the immunosuppressant IL-10 compared with control was increased in cells treated with Fc or LPS. However, the expression of IL-12 (p70) in cells treated with Fc was lower than during stimulation with lipopolysaccharide (Fig.6). Fc stimulated the ability of DCs to Express TNF-α, and the expression level comparable to the level obtained by treatment of LPS. The expression of IFN-γ in T cells increased when dendritic cells with T cells at a ratio of 1:25 were treated with Fc or LPS (Fig.7).

The definition of the functionality is through the activity of dendritic cells (mixed lymphocyte culture)

T cells were purified from peripheral blood of healthy volunteers, and the purity was tested by staining with FITC-conjugated CD3 antibodies. Fc or LPS-treated dendritic cells were treated with 50 μg/ml of mitomycin C for 1 h and then 1×105T cells were added to 96 well plates. Cells were cultivated for 5 days at 37°C, 5% CO2and then add 1 µci of [3H]thymidine (NEN-DuPont, Boston, MA). The radioactivity of the collected cells was measured after 18 hours Testing dendritic cells for their ability to support the activation of T-cells showed that they stimulated the proliferation of T cells, when grown for 5 days in the ratio (T:DC=1:25) (Fig).

The use of fucoidan from Fucus evanescens or polysaccharide composition of Fucus evanescens, consisting of fucoidan in the amount of 60-80% and polymannuronic acid in the amount of 20-40%, as a means of inducing the maturation of dendritic cells.


Same patents:

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary science, in particular, to ways of reception of immunomodulatory and antiseptic compounds for prevention and treatment of infectious diseases of animals. The way of reception of a complex immunotropic antiseptic preparation for prevention and treatment of infectious diseases of animals includes mixing of an amber acid, novocaine, Dorogov's antiseptic-stimulator of the second fraction and formalin in water at a following parity of components, wt %: amber acid 1; DAS №2 4; novocaine 0.25; formalin 0.4; the distilled water - the rest, and sterilisation using autoclave treatment which is performed in a 1 atm regimen. Within 20 minutes. The received compound possesses antiseptic, immunomodulatory and trophicostimulating activity at a parenteral way of introduction.

EFFECT: rising of efficiency of the received preparation at treatment and prevention of infectious diseases of animals.

2 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to creation of immunogene compositions and vaccines for prevention or treatment of the infections caused by Gram-negative bacteria. The immunogene compositions containing a transferrin-binding fiber and Hsf, and a way of their reception are offered. It is shown, that the combination of these two antigens synergically influences on production of antibodies with high activity in the analysis of bactericidal Serum. The composition can be used in vaccines against Gram-negative bacteria, including Neisseria meningitides, Neisseria gonorrhoeae.

EFFECT: creation of immunogene compositions and vaccines for prevention or treatment of the infections caused by Gram-negative bacteria.

56 cl, 10 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention concerns area of medical products, in particular to application of complex bonds of iron (III) with carbohydrates or their derivatives for reception of a medical product for improvement of immune protection and-or activity of a brain at patients without an anaemia caused by deficiency of iron or deficiency of iron in which complex bond of iron (III) is iron (III)-polymaltose complex bond or complex bond of iron (III) with a product of oxidation one or several maltodextrins.

EFFECT: development of preparations for improvement of immune protection and-or activity of a brain at patients without an anaemia caused by deficiency of iron or deficiency of iron.

7 cl, 1 tbl, 1 ex

FIELD: medicine; pharmacology.

SUBSTANCE: substance of technical decision seeks to produce immunopotentiating composition based on nanotechnology products, specifically fullerenes and superdispersed diamond powders (nanodiamonds) produced by detonation synthesis. Composition contains modified fullerene of general formula C60-X, where C60 is fullerene nucleus, X is formylporphyrin, as well as superdispersed diamond powder in ratio as follows, wt %: porphyrin modified fullerene C60 - 50; superdispersed diamond powder - 50.

EFFECT: synergetic effect of immunopotentiating components activity with simultaneous considerable reduction in price concerning prototype composition.

2 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: autoblood is daily sampled in patient as 2 ml/kg of weight. Sampled blood is mixed with 20 ml of 0.06% sodium hypochlorite with further ultraviolet radiation with the help of "Isolda" device for 20 minutes. Then blood is intravenously injected to by drop infusion. Treatment is carried out daily for 5 days.

EFFECT: enhanced efficiency of treatment of patients with chronic obstructive bronchitis.

2 ex, 2 tbl

FIELD: medicine; immunology.

SUBSTANCE: human immune system is stimulated with using osmium iridium mineral dispersed to 0.1 mcm. Then dispersed osmium iridium is separately mixed with medicinal bitumen in ratio 1:1000. Produced composition is processed in vacuum chamber at pressure 0.01-0.001 atm and temperature 20-30°C within 2-4 hours and in autoclave at pressure 5-10 atm and temperature 60-80°C within 5-10 hours. Produced composition is injected to human body.

EFFECT: method allows for immune system stimulation, improved organism protected from adverse factors affecting self-regulation and self-regeneration processes.

2 tbl

FIELD: chemistry, immunology.

SUBSTANCE: extraction of dried cook water of sea cucumber Cucumaria frondosa or dried powder tissues of Cucumaria frondosa by chloroform and methanol mix is performed during boiling with reflux condenser to obtain organic extract; extract is evaporated, evaporated extract is re-dissolved in water, obtained colloid solution is decanted, ethylacetate is added to solution, water phase is decanted and undergoes chromatography in teflon or silica gel columns. Immune system activity of mammals, including lizosomic activity, phagocitosis and active oxygen form generation in macrophags of mammals, infected with bacterial cells, viruses and protozoa, is stimulated by oral, intraperitoneal or intramuscular or combined introduction of frondosite A dosage of 1 to 15 mcg/kg, preferably 10 mcg/kg.

EFFECT: implementation of claimed objective.

11 cl, 18 ex

FIELD: medicine.

SUBSTANCE: composition includes a deoxyribonucleic acid, vitamins B1, B6, acidum ascorbinicum, L-arginin, vitamins B12, PP, acidum folicum and vitamin P, in any biologically comprehensible form in the following quantities. The invention provides expansion of assortment of the preventive preparations possessing as invigorating, immunomodulating, antistress, and angioprotecting actions, besides, at influence on an organism of all substances listed in a composition gives a synergistic effect, besides application of components of a composition in the declared doses, allows to level those by-effects inherent to components of a preparation, applied separately.

EFFECT: increased preventive; invigorating; immunostimulating and angioprotecting actions.

3 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns medicine. A soft drink on the basis of herbs consists of the concentrated vegetative extract obtained from an admixture of herbs, chosen of Sida sps., Boerhaavia diffusa, Vitis vinifera, Tinospora cordifolia and Withania somnifera, along with green palm sugar, the agent causing a fermentation, and carbonised water, in which proportion Sida sps.: Boerhaavia diffusa: Vitis vinifera: Tinospora cordifolia: Withania somnifera in a powdery admixture makes (15-20 : (5-10 : (15-20 : (5-10 : (5-10); Proportion of wt/wt: green palm sugar: the concentrated vegetative extract makes from 1 : 3 to 1 : 4; wt/wt, a proportion of carbonised water: the admixture of the concentrated vegetative extract, green palm sugar and the agent causing a fermentation, makes from 1 : 3 to 1 : 5. Perform: (a) obtaining of parts of Sida sps., Boerhaavia diffusa, Vitis vinifera, Tinospora cordifolia and Withania somnifera; (b) crushing of parts of plants and their mixing with obtaining of a powdery admixture; (c) water addition to a powdery admixture from a stage (b) for obtaining of a water extract; (d) concentration of a water extract from the stage (c); (e) filtration of the concentrated extract from the stage (d); (f) admixture of green palm sugar to the filtered extract from the stage (e); (g) addition of Sacromyces strain and the agent causing fermentation, to the admixture from the stage (f); (h) fermentation of the admixture from the stage (g) during the period of time from 3 till 6 days; (i) filtration of the fermented admixture from the stage (h); (j) concentration of the fermented filtrate from the stage (i) with obtaining of the basic solution and (k) mixing of the basic solution (j) with the carbonised water in wt/wt proportion from 1 : 3 to 1 : 5 with obtaining of a soft drink on the basis of herbs.

EFFECT: creation of a soft drink on the basis of herbs.

11 cl, 5 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: prevention method of acute respiratory infections is developed for children with frequent recurrent diseases of respiratory tract. It consists in simalteneous administration of arbidol - 1 tablet (50 mg) twice a week during 3-4 weeks combined with selenium-active - 0.5 tablet (25 mcg of selenium) once a day during 3-4 weeks. In the course of 12 months the method helps to reduce frequency and general time duration of respiratory diseases by factor of 1.9 due to simulteneous correction of immune and metabolic state disorders.

EFFECT: reduction of frequency and general time duration of respiratory diseases.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medical products and concerns the dosed out form for introduction to a mammal, intended for treatment or prevention of a disease state at a mammal mediated by action of PARP where the dosed out form contains chemical combination of formula 1, its pharmaceutically comprehensible salt or a solvate, or their admixtures, in quantity, effective for maintenance of stable size of concentration in plasma, at least, 5.9 ng/ml of the formula chemical combination within, at least, 24 hours after introduction in an organism of a mammal which is the concentration of an inhibitor suppressing (IC89) consumption of cellular NAD+ on 89% and formation of polymer of poly ADP-ribose, and it is corrected taking into account linkage with a protein. The offered dosed out form provides stable size of concentration in plasma of 5.9 ng/ml of AG-014699 within, at least, 24 hours after introduction in an organism of a mammal.

EFFECT: maintenance of effective treatment and prevention of a disease state at a mammal mediated by PARP action.

85 cl, 4 dwg, 23 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, in particular to experimental oncology, and concerns increase of antitumoral effect of chemotherapy. For this purpose introduction of an antitumoral preparation is alternated on days to introduction of the ozonised normal saline solution with concentration of ozone in the ozone-oxygen admixture by of 0.2 mg/l and gas flow rate of 0.5 l/min; the general course makes 10 days. Introduction of a normal saline solution with such characteristics in the developed regimen allows to raise efficiency of antitumoral chemotherapy considerably.

EFFECT: rising of efficiency of antitumoral chemotherapy.

5 ex, 5 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: present invention concerns medicine, namely - to oncology and can be used for treatment of a cancer at a mammal. The way under the invention includes introduction of ditosylate salt N-{3-chloride-4-[(3-fluobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethylene]amino}methyl)-2-furyl]-4-quinazoline amine (chemical combination 1) monohydrate and capecitabine.

EFFECT: depression of risk of advance of disease.

2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: application of a fluridon herbicide (1-methyl-5 (α,α,α-trifluoro-m-tolyl)-3-phenylpyridinon-4) of the structural formula (I) as an agent for treatment of oncologic diseases with a disposable dosage from 0.1 mg to 5 g on reception to 3 times a day is offered. It is possible to take fluridon in the form of a dry powder or as an aqueous solution in rectal, intravenous or intraperitoneal manner, in the form of ointment, candles, or inhalant. Efficiency of treatment of oncologic diseases is shown: adenocarcinoma, melanoma with metastasises, carcinoma, non-Hodgkin's lymphoma, liver cancer, glioblastoma, and sarcoma.

EFFECT: development of a substance which suppresses proliferation of cancer cells more effectively than doxorubicine, does not cause by-effects in patients at its use.

8 cl, 5 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: invention relates medicine, namely to oncology, and concerns treatment of a local non-small cell carcinoma of lung. Courses of preoperative system polychemotherapy with an interval of 3 weeks are used for this purpose. Each course is spent within one day, thus the course includes unitary intravenous drop introduction of taxotere in a dose of 65 mg/m2 and then cisplatinum in a dose of 65 mg/m2. The polychemotherapy is spent before achievement of the maximum effect. Then in 3 weeks the radical operation with an intraoperational radical therapy in a single dose of 15 g is carried out.

EFFECT: improvement of results of treatment at the expense of reduction of the complications bound to system polychemotherapy and, as consequence, depression of number of postoperative complications, improvement of quality of life of patients.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to oncology, and can be used in complex, organ-preserving treatment of breast cancer. Essence of the invention lies in the following: operative interference starts from liposuction of abdomen or hips. Then adipose tissue in required volume depending on volume of part of mammary gland subjected to removal is placed into vessel with 5-fluorurocyl 100 mg and cyclophosphane 400 mg, the vessel is incubated during 40 minutes at 37°C. Then organ-preserving operation on mammary gland is performed, after the end of which remaining pat of mammary gland is infiltrated with incubated adipose tissue with chemical preparations from the vessel.

EFFECT: reduction of frequency of cancer recurrences, improvement of esthetic results of organ-preserving operations due to recovery of volume of operated mammary gland with autologic adipose tissue incubated with chemical preparations.

1 ex

FIELD: chemistry; medicine.

SUBSTANCE: claimed are polypeptide and respective polynucleotide zcytor17lig and molecules of antibody against human zcytor17. Human zcytor17lig is novel cytokine. Claimed invention also relates to methods of protein obtaining, its application for stimulation of immune reaction in mammal. Described is method of obtaining antibodies to said protein and respective antibodies.

EFFECT: polypeptides can be used in realisation of methods stimulation of immune system, proliferation and development of hemopoietic cells in vitro and in vivo.

17 cl, 3 dwg, 21 tbl, 47 ex

FIELD: medicine.

SUBSTANCE: in 1st, 9th, 17th and 24th days of therapy, 5-fluorouracil 750 mg and cisplatin 30 mg incubated with autoblood are introduced intravenously. In 7th, 15th and 23rd days, cisplatin 10 mg incubated with autoplasma, Novocaine 0.5% 20 ml, hydrocortisone 1.0 ml, analginum 50% 2.0 ml, vitamin B12 1.0 ml and gentamycin 1.6 g are introduced into presacral of small pelvis. From 10th to 14th days, 2 hours prior to radiotherapy session, a mixture containing Doxorubicin-Ebewe 5 mg, Viferon ointment 2.5 mg, Vinilin 2 ml, Synthomycin emulsion 2 ml and Dimexide 5% 4 ml is supplied to primary-site tumour through a perforated rubber tube. From 18th to 22th days, a mixture containing Mitomycin C 2.5 mg, Viferon ointment 2.5 mg, Vinilin 2 ml, Synthomycin emulsion 2 ml and Dimexide 5% 4 ml is supplied to primary-site tumour through a perforated rubber tube. After an 14-day recess, the therapeutical actions are repeated once again as specified.

EFFECT: involution of tumour, reduced radiation exposure and toxic by-effects of antitumour therapy.

1 ex

FIELD: medicine.

SUBSTANCE: triterpene glycosides from holothurians are applied to prepare the pharmaceutical composition stimulating apoptosis of human leukaemia cells.

EFFECT: agent described above stimulates apoptosis of human leukaemia cells effectively and does not affect normal cells of human immune system.

3 cl, 14 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and can be used for therapy of tumours. Substance of the invention consists in application of 3,3'-diethylthiatricarbocyanine iodide C25H25N2S2·I of structural formula: as an agent used in oncotherapy at single dosage 0.1 mg to 5 g taken up to 3 times a day.

EFFECT: invention allows improving therapeutic effectiveness ensured by recovered polarisation of molecules in introduction of low-toxic 3,3'-diethylthiatricarbocyanine iodide without by-effects.

9 cl, 13 ex

FIELD: food industry.

SUBSTANCE: invention relates to diet composition containing vasoprotective agents and used for prevention of vascular disorders caused by excess of plasma lipids. Diet composition includes one or several polycosanols or their esters in pure form or in form of extracts, tocotrienol and/or licopene, one or several procyanidole oligomers optionally in form of complex with phospholipids, vegetable oil, enriched with ω-3, ω-6 unsaturated fatty acids.

EFFECT: reduction of cholesterol and triglycerides content in blood, protecting vessel walls against damage connected with excessive production of free radicals and oxidised forms of cholesterol, which ensures strengthening of vessel walls.

18 cl, 1 tbl, 5 ex